Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Review Article

SRP. 2011; 2(1): 43-47


Cardiovascular Indications and Complications of Recombinant Human Erythropoietin

Vekaria A, Gigani Y, Belemkar S.

Abstract
Exogenous recombinant human erythropoietin (rHuEPO) is a beneficial therapeutic agent for
correction of anemia in chronic kidney disease (CKD), end-stage renal disease, chemotherapy,
and has been used as prophylaxis to prevent anemia after surgery. The erythropoietin receptor
is widely distributed in the cardiovascular system, including endothelial cells, smooth muscle
cells and cardiomyocytes. RHuEPO has potentially beneficial effects on the endothelium including
cytoprotective, mitogenic and angiogenic activities. Early studies in heart failure patients with
anemia suggest that rHuEpo therapy is safe and effective in reducing left ventricular hypertrophy,
enhancing exercise performance and increasing ejection fraction. The use of rHuEPO, however,
may also be associated with distinct side effects. Although not clearly demonstrated, a relationship
between an increased red blood cell count and thrombus formation. Some reports suggest
that rHuEpo may have prothrombotic or alters platelet aggregatory responses. Most notable is
hypertension (HTN), partial correction of anemia with intravenous rHuEPO causes HTN. CREATE
study found a trend toward increased mortality risk with a higher Hb target of 13-15 g/dl. Therefore
aiming for a higher hematocrit level is still a controversial issue in the management of anemia
in renal failure. Despite some potential adverse effects further studies are needed to define the
role of rHuEPO in chronic cardiovascular settings.

Key words: Cardiovascular mortality CHOIR study Chronic kidney disease Recombinant human erythropoietin



Similar Articles

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL, Gómez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-Díaz JC, Sánchez-González VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37

Dendritic spine density changes and homeostatic synaptic scaling: a meta-analysis of animal studies.
Moulin TC, Rayêe D, Schiöth HB
Neural regeneration research. 2022; 17(1): 20-24

extract promotes M2 polarization and reduces oligomeric amyloid-β-induced inflammatory reactions in microglial cells.
Sun ZQ, Liu JF, Luo W, Wong CH, So KF, Hu Y, Chiu K
Neural regeneration research. 2022; 17(1): 203-209

Ghrelin alleviates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells.
He X, Yuan W, Yang CQ, Zhu L, Liu F, Feng J, Xue YX
Neural regeneration research. 2022; 17(1): 170-177


Full-text options


Add your Article(s) to Indexes
• CiteIndex: Articles & Statistics







Advertisement
American Journal of Diagnostic Imaging

SUBMIT YOUR ARTICLE NOW




ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.